Strategy and business model

Strategy and business model

NorInvent's Drug Delivery platform, XtriG, shall be general and target the entire global pharmaceutical industry as an alternative form of preparation. XtriG may challenge both oral and per oral preparations but primarily the tablet form. Tablets are today one of the most common drug preparations.

The goal is that XtriG will open the market for oral administration in a way that has not been possible before. The revenue model is based on out-licensing of the platform where remuneration is obtained through upfront, milestone and/or royalty payments.

Business Concept

NorInvent's business idea is to license the platform to global pharmaceutical companies for compensation in the form of Upfront, Milestone and Royalty payments.


The visionen is to introduce a carbohydrate based Drug Delivery platform to global pharmaceutical companies.


Our mission is to improve the profitability and properties of existing pharmaceuticals through the company's patented technology.